(P019) Patterns and Predictors of Local Failure in Cervical Cancer

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Para-aortic lymphatic failure occurred in 14.5% of patients in our study. Para-aortic failures occurred in 17.7% of patients with ≥ 3 lymph nodes and in 19.5% of patients with pelvic lymph nodes ≥ 1.5 cm. This may suggest the need for escalation of radiotherapy or chemotherapy in these patients.

Alfredo Echeverria, MD, Umang Patel, MD, John Shumway, BA, Mark Bonnen, MD, Michelle Ludwig, MD, MPH, PhD; Baylor College of Medicine

PURPOSE: To identify factors at the time of presentation that predict for para-aortic lymphatic failures after definitive chemoradiation and to map out specific patterns of nodal failure.

METHODS: We identified 138 patients with IB1–IVA cervical cancer treated with definitive chemoradiation between 2008 and 2014. Information on tumor size and stage was gathered. The number, size, and specific lymph node location were recorded before therapy and at the time of any failure. Treatment-related data included modality, dose, and fields of radiation, as well as the number of chemotherapy cycles.

RESULTS: Eighty-two (59.0%) patients presented with nodal disease, all of whom had pelvic lymph node involvement, with a mean of six involved nodes. Thirty-three (23.7%) presented with para-aortic chain involvement and a mean of five involved nodes. Mean primary tumor volume was 131.7 cc. Median follow-up was 23 months. Two-year progression-free survival (PFS) and overall survival (OS) were 69% (standard error [SE], 0.04) and 88% (SE, 0.03), respectively. Tumor size at presentation (P = .003), fewer cycles of chemotherapy (P = .02), and ≥ 3 lymph nodes (P = .00) were adversely associated with PFS. Locoregional and distant failures occurred in 24 (17.3%) and 18 (12.9%) patients, respectively. There was a 10.1% rate of primary site failures vs 6.5% in the pelvic lymph nodes, 1.4% in the inguinal lymph nodes, and 14.5% in the para-aortic chains. Patients at higher risk for para-aortic failure were those with lymph nodes ≥ 1.5 cm in the shortest axis (19.5% vs 7.8%; P = .05) and those with ≥ 3 involved pelvic nodes (17.7% vs 5.8%; P = .03).

CONCLUSIONS: Para-aortic lymphatic failure occurred in 14.5% of patients in our study. Para-aortic failures occurred in 17.7% of patients with ≥ 3 lymph nodes and in 19.5% of patients with pelvic lymph nodes ≥ 1.5 cm. This may suggest the need for escalation of radiotherapy or chemotherapy in these patients. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content